Summary
Plasma and knee joint synovial fluid (SF) concentration of diclofenac sodium and its hydroxylated metabolites were measured after chronic dosing with the 100 mg polymer matrix formulation. Peak concentrations were reached in plasma and SF roughly after administration. Plasma concentrations then fell rapidly, but concentrations in SF were maintained for up to 25 h. The active metabolite was present in both fluids throughout the study period. The slow-release form showed a longer plasma/SF equilibration time than the conventional tablet had in a previous study. Prostaglandin E1 and F2a concentrations were lower in the early post-dose period but did not correlate with drug concentrations.
Similar content being viewed by others
References
Fowler PD, Shadforth MF, Crook PR, John VA (1983) Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during long-term treatment of rheumatoid arthritis. Eur J Clin Pharmacol 25: 389–394
Menasse R, Hedwell PR, Kraetz J, Pericin C, Riasterer L, Sallman A, Ziel R, Jaques A (1978) Pharmacological properties of diclofenac sodium and its metabolites. Scand J Rheumatol [Suppl] 22: 2–16
Schneider W, Degen PH (1981) Simultaneous determination of diclofenac and its hydroxylated metabolites by capillary column gas chromatography with electron capture detection. J Chromatogr 217: 263–271
Wallis WJ, Simkin PA (1983) Antirheumatic drug concentrations in human synovial fluid and synovial tissue. Clin Pharmacokinet 8: 486–522
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fowler, P.D., Dawes, P.T., John, V.A. et al. Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during once-daily administration of a 100 mg slow-release formulation. Eur J Clin Pharmacol 31, 469–472 (1986). https://doi.org/10.1007/BF00613526
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00613526